Open Access<p>Prevalence of <em>CYP2C8*2</em> and <em>*3</em> among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment</p>
Author(s) -
Lidia Habtemikael,
Mulugeta Russom,
Iyassu Bahta,
Selam Mihreteab,
Araia Berhane,
Andreas Mårtensson,
José Pedro Gil
Publication year - 2020
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s276215
Subject(s) - medicine , artesunate , amodiaquine , immunology , chloroquine , malaria , plasmodium falciparum
In Eritrea, artesunate-amodiaquine is the first-line treatment against uncomplicated malaria. Amodiaquine, which is mainly bio-transformed by CYP2C8, is known to be associated with adverse events of different severity. Extrapyramidal events are among the less common but have been reported with non-negligible frequency in Eritrea. This study was conducted to investigate the allele frequencies of CYP2C8*2 and *3 , both associated with decreased amodiaquine metabolism, among the Eritrean population.